ENGLISH ABSTRACT
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

[Surgical therapy of pelvis and spine in primary malignant bone tumors].

Der Orthopäde 2003 November
Despite standardization of surgical treatment of primary malignant tumors of the pelvis and spine, prognosis in these centrally located tumors still is inferior compared to those located in the extremities. This fact may be attributed to delayed diagnosis in many cases and the resulting increase in tumor volume as well as to difficulties of resection due to the anatomical situation. The frequency of local recurrence after resection of primary malignant tumors is reported to be between 4 and 41% and the 5-year survival rate below 40%. Whereas the latter has remained almost unchanged during the past 20 years, amputation has been replaced by limb-salvage surgery except for a minimal amount of less than 10%. For reconstruction, biological techniques are increasingly preferred to endoprosthetic replacement or use of bulk allografts because of the high complication rate. Even in the spine wide resections are feasible provided at least one lamina is healthy in order to prepare and save the neural structures without touching the tumor. Compared to the widely used technique of curettage, en bloc resection may provide a significantly better oncologic result with respect to local tumor control. Failure of the dorsoventral stabilization with delayed union is the most frequent complication of these challenging procedures. In order to improve the long-term prognosis of these groups of patients in the future, early diagnosis and immediate admission to a specialized tumor service has to be attempted.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app